MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Aerie Pharmaceuticals Company Profile (NASDAQ:AERI)

Consensus Ratings for Aerie Pharmaceuticals (NASDAQ:AERI) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $45.71 (161.08% upside)

Analysts' Ratings History for Aerie Pharmaceuticals (NASDAQ:AERI)
Show:
DateFirmActionRatingPrice TargetActions
6/2/2016Cantor FitzgeraldInitiated CoverageBuy$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/5/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2015JMP SecuritiesBoost Price TargetOutperform$39.00 -> $49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2015Needham & Company LLCBoost Price TargetBuy$27.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2015Stifel NicolausBoost Price TargetBuy$30.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/5/2015Piper Jaffray Cos.Reiterated RatingBuy$7.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2015MLV & Co.Reiterated RatingBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for Aerie Pharmaceuticals (NASDAQ:AERI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/2/2016Q116($0.64)($0.72)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2016Q415($0.72)($0.64)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.66)($0.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.70)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.62)($0.70)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.46)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014($0.40)($0.54)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014($0.34)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.35)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2014Q413($0.25)($0.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/4/2013Q313($0.25)($10.81)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Aerie Pharmaceuticals (NASDAQ:AERI)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Aerie Pharmaceuticals (NASDAQ:AERI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Aerie Pharmaceuticals (NASDAQ:AERI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/15/2015Anand MehraDirectorSell425,000$33.64$14,297,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell175,000$31.11$5,444,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell23,620$30.86$728,913.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell80,724$30.05$2,425,756.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,704$30.36$1,509,013.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,441$30.36$1,501,028.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Anand MehraDirectorSell800,000$26.00$20,800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Group Holdings (Sbs) Advis TpgInsiderSell1,300,000$25.97$33,761,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell1,000,000$25.17$25,170,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell500,000$25.05$12,525,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Anand MehraDirectorSell323,932$16.00$5,182,912.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Iv L.P. AcpMajor ShareholderSell300,000$16.00$4,800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Gerald CagleDirectorBuy1,854$15.07$27,939.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Brian LevyInsiderBuy6,000$10.00$60,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Iv L.P. AcpMajor ShareholderBuy110,000$10.00$1,100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Richard J RubinoCFOBuy10,000$10.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Thomas A MitroCOOBuy5,000$10.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Vicente Anido JrCEOBuy28,000$10.00$280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Anand MehraDirectorBuy285,000$10.00$2,850,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Lifesciences Ii L.P. ClarusMajor ShareholderBuy321,000$10.00$3,210,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Aerie Pharmaceuticals (NASDAQ:AERI)
DateHeadline
07/01/16 10:18 AMAerie Pharmaceuticals, Inc. (AERI) Updated Price Targets - FTSE News
06/30/16 02:21 PMAerie Pharmaceuticals, Inc. (AERI) Current Analyst Ratings - Fiscal Standard
06/29/16 02:17 PMAerie Pharmaceuticals Inc. (AERI) Jumps 6.41% on June 28 - Equities.com
06/28/16 07:33 AMCovering the Bases on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): Where is the Stock Going? - Press Telegraph
06/27/16 07:06 AMAerie Pharmaceuticals, Inc. (AERI) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 07:34 PMStrong Sell Calls Recommendations For Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) At 0 - Investor Newswire
06/24/16 10:16 AMNew Broker Ratings For Aerie Pharmaceuticals, Inc. (AERI) - FTSE News
06/23/16 03:47 PMAerie Pharmaceuticals : Patent Issued for 6-Aminoisoquinoline Compounds (USPTO 9365518)
06/23/16 10:05 AMAERIE PHARMACEUTICALS INC : Other Events (form 8-K)
06/22/16 02:21 PMAerie Pharmaceuticals, Inc. (NasdaqGM:AERI) Stock Momentum at Critical Inflection Point - CML News
06/22/16 05:31 AMAERIE PHARMACEUTICALS INC Files SEC form 8-K, Other Events -
06/21/16 07:06 AMRecently Issued Stock Ratings For Aerie Pharmaceuticals, Inc. (AERI) - Fiscal Standard
06/20/16 02:19 PMEarnings in Focus: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - iStreetWire
06/19/16 02:19 PMGlobal Diabetic Retinopathy Pipeline Report 2016 - Review of 41 Therapeutics Companies & Drug Profile Activity - Research and Markets
06/19/16 07:04 AMThis Weeks Broker Views For Aerie Pharmaceuticals, Inc. (AERI) - Fiscal Standard
06/18/16 07:03 AMStrong Buy Calls Count For Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) At 4 - Investor Newswire
06/17/16 02:18 PMCompany Update (NASDAQ:AERI): Aerie Pharmaceuticals Inc Completes Enrollment of Rocket 4 Phase 3 Clinical Trial ... - Smarter Analyst
06/17/16 10:15 AMAERIE PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
06/16/16 09:55 AMAerie Pharma stays on track with late-stage trial enrollment -
06/16/16 08:55 AMAerie Completes Enrollment Of Rocket 4 Final Stage Clinical Study Of RhopressaTM 0.02% -
06/16/16 07:39 AMAerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of RhopressaTM (netarsudil ophthalmic solution) 0.02% - [at noodls] - June 16, 2016 - Trial On Track for Topline 90-day Interim Efficacy Readout in Q4 2016 - -Rocket 4 Designed for EU Filing; Not Required for US NDA Filing- IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, ...
06/16/16 06:02 AMAerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of RhopressaTM (netarsudil ... - Business Wire (press release)
06/15/16 02:21 PMDiabetic Retinopathy 2016 Pipeline Market Review Research
06/15/16 07:08 AMAerie Pharmaceuticals : Assigned Patent
06/09/16 03:32 PMAERIE PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/09/16 11:04 AMCantor Fitzgerald Initiates Coverage on Aerie Pharmaceuticals Inc to Buy - Trade Calls
06/08/16 08:34 PMForm 8-K AERIE PHARMACEUTICALS For: Jun 08
06/08/16 10:48 AMForm 8-K AERIE PHARMACEUTICALS For: Jun 08 - StreetInsider.com
06/05/16 10:12 AMAerie Pharmaceuticals Incorporated (NASDAQ:AERI) Shorted Shares Increased By 3.93% - HNN
06/05/16 10:12 AMAfter Last Week What Do Analysts Think Of Aerie Pharmaceuticals, Inc. (AERI) - Share Trading News
06/04/16 10:47 AMAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Stock Update & Estimates - Stock Tick Tock
06/03/16 08:22 PMAnalysts Offer Insights on Healthcare Companies: Aerie Pharmaceuticals Inc (NASDAQ: AERI), Dimension ... - Analyst Ratings
06/03/16 10:48 AMAerie Pharmaceuticals Inc. (AERI) Jumps 7.56% on June 02 - Equities.com
06/03/16 10:48 AMAerie Pharmaceuticals Inc 122.8% Potential Upside Now Implied by Cantor Fitzgerald - DirectorsTalk Interviews
06/02/16 06:35 AMAerie Pharmaceuticals to Participate in Two Investor Conferences in June - [at noodls] - June 2, 2016 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class ...
06/01/16 10:43 AMBroker Watchlist: Aerie Pharmaceuticals, Inc. (AERI) - Share Trading News - Broker Watchlist: Aerie Pharmaceuticals, Inc. (AERI)Share Trading News03/18/2016 – Aerie Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 40 price target on the stock. 02/18/2016 – Aerie Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at ...Stock Trending Up: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)The PostAerie Pharmaceuticals, Inc. (AERI) Updated Broker RatingsRisers & Fallersall 12 news articles »
05/31/16 08:02 PMShare Rating Focus on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - HNN - Share Rating Focus on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.25 on shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus ...and more »
05/30/16 09:18 PMHow Many Aerie Pharmaceuticals Inc (NASDAQ:AERI)'s Analysts Are Bearish? - HNN - How Many Aerie Pharmaceuticals Inc (NASDAQ:AERI)'s Analysts Are Bearish?HNNOut of 6 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aerie Pharmaceuticals has been the topic of 10 analyst reports since August 7, 2015 according to ...and more »
05/30/16 09:18 PMHow Many Aerie Pharmaceuticals Inc (NASDAQ:AERI)'s Analysts Are Bearish? - HNN - How Many Aerie Pharmaceuticals Inc (NASDAQ:AERI)'s Analysts Are Bearish?HNNOut of 6 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aerie Pharmaceuticals has been the topic of 10 analyst reports since August 7, 2015 according to ...and more »
05/22/16 06:23 PMAlpha One Assigns Impact Score Of 0 To Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Investor Newswire - Alpha One Assigns Impact Score Of 0 To Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)Investor NewswireAlpha One analyzed the various web articles published on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), and thereafter it gave company a daily sentiment score of 0.435. The entity designs algorithm based assessment to known stock sentiment on stock after ...and more »
05/21/16 06:28 PMAerie Pharmaceuticals Inc (AERI) Drops 6.21% on May 19 - Equities.com - Aerie Pharmaceuticals Inc (AERI) Drops 6.21% on May 19Equities.comAerie Pharmaceuticals Inc (AERI) was one of the Russell 2000's biggest losers for Thursday May 19 as the stock slid 6.21% to $14.65, a loss of $-0.97 per share. Starting at an opening price of $15.52 a share, the stock traded between $14.62 and $16.04 ...and more »
05/20/16 06:54 PMDrug Manufacturers Volatile Stocks: Alliqua Biomedical Inc (NASDAQ:ALQA), Aerie Pharmaceuticals, Inc. (NASDAQ ... - KC Register - Drug Manufacturers Volatile Stocks: Alliqua Biomedical Inc (NASDAQ:ALQA), Aerie Pharmaceuticals, Inc. (NASDAQ ...KC RegisterOn 5 May, Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced the completion of patient enrollment in the Company's initial Phase 3 registration trial (“Mercury 1”) of RoclatanTM(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel ...and more »
05/19/16 06:55 PMTraders’ Choice – GBSN, SAAS, ANDE, CCXI, MGNX, FIVN, ZAIS - The company is -77.32 pct year-to-date, and -80.50 pct during the past four quarters. Aerie Pharmaceuticals Inc (AERI) traded at $15.60 + 1.91 (13.92 pct) on 562,831 total stock volume. The company is -35.95 pct year-to-date, and +39.22 pct during the ...
05/19/16 06:55 PMNotable Wednesday Option Activity: BOX, AERI, AIG - Today's Most Active Call & Put Options of the S&P 500 » Aerie Pharmaceuticals Inc (NASDAQ:AERI) saw options trading volume of 1,540 contracts, representing approximately 154,000 underlying shares or approximately 43.8% of AERI's average daily trading ...
05/18/16 06:57 PMRevenue Update on Aerie Pharmaceuticals Inc(NASDAQ:AERI) - Trade Calls - Revenue Update on Aerie Pharmaceuticals Inc(NASDAQ:AERI)Trade CallsAerie Pharmaceuticals Inc(NASDAQ:AERI) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 2, 2016. Earnings per share were $-0.72. Analysts had estimated an EPS of $-0.64. Aerie Pharmaceuticals ...Aerie Pharmaceuticals Inc (NASDAQ:AERI)'s Company Shares Decreased 10.93% After Low VolatilityWall Street Hints and NewsAerie Pharmaceuticals Incorporated (NASDAQ:AERI) Sellers Increased By 10.19% Their ShortsThe Postall 4 news articles »
05/18/16 06:57 PMAerie Pharmaceuticals Inc (AERI) Jumps 14.1% on May 18 - Equities.com - Aerie Pharmaceuticals Inc (AERI) Jumps 14.1% on May 18Equities.comAerie Pharmaceuticals Inc (AERI) was among the biggest gainers on the Russell 2000 for Wednesday May 18 as the stock popped 14.1% to $15.62, representing a gain of $1.93 per share. Some 745,489 shares traded hands on 5,680 trades, compared with ...and more »
05/18/16 03:21 PMThis lingerie brand for young women refuses to airbrush ads — and sales are soaring 32% -
05/17/16 11:50 PMAerie Pharmaceuticals Inc (AERI) Jumps 7.35% on May 16 - Equities.com - Aerie Pharmaceuticals Inc (AERI) Jumps 7.35% on May 16Equities.comAerie Pharmaceuticals Inc (AERI) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 7.35% to $13.88, representing a gain of $0.95 per share. Some 364,335 shares traded hands on 2,966 trades, compared with an ...and more »
05/16/16 06:39 PMAnalysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (NASDAQ: GLMD), Aerie Pharmaceuticals ... - Markets.co - Analysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (NASDAQ: GLMD), Aerie Pharmaceuticals ...Markets.coThere's a lot to be optimistic about in the Healthcare sector as 3 experts just weighed in on Galmed Pharmaceuticals (NASDAQ: GLMD), Aerie Pharmaceuticals Inc (NASDAQ: AERI), AVEO Pharmaceuticals (NASDAQ: AVEO) and Pluristem Therapeutics ...
05/11/16 06:03 AMAERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
About Aerie Pharmaceuticals

Aerie Pharmaceuticals logoAerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AERI
  • CUSIP:
Key Metrics:
  • Previous Close: $17.51
  • 50 Day Moving Average: $17.15
  • 200 Day Moving Average: $16.74
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $464.51M
  • Current Quarter EPS Consensus Estimate: $-2.69 EPS
Additional Links:
Aerie Pharmaceuticals (NASDAQ:AERI) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha